Salute e Benessere

Medical Spa Market Size worth $49.4 billion by 2030 with 15.13% CAGR - Exclusive…

For More Information and To Stay Updated on The Latest Developments in The Medical Spa Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=9889 For More Information and To Stay Updated on The Latest Developments in The Medical Spa Market Share, Download FREE Sample Pages: https://www.theresearchinsights.com/request_sample?id=9889 Market Overview and Growth Trajectory: Medical Spa Market Growth: According to an exhaustive report by...
PR Newswire
12/06/2025

As Public Cancer Funding Wavers, Oncology's Brightest Breakthroughs Are Coming…

VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The 2025 ASCO Annual Meeting has wrapped, leaving behind a wave of cautious optimism across the oncology landscape. From advances in immunotherapy and CAR T-cell strategies to new applications in AI, diagnostics, and even exercise-based interventions, this year's gathering spotlighted a broad array of promising approaches. However, looming over the scientific excitement are concerns about proposed U.S. budget cuts…
PR Newswire
12/06/2025

After Major Oncology Conference, All Eyes Turn to Industry Innovation

VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the…
PR Newswire
12/06/2025

Reacta Healthcare announces transformation into a facility for multi-allergen…

The addition of egg and milk challenge meals to the existing peanut products at Reacta Healthcare reflects the prevalence of multiple food allergies. These products are designed to meet the needs of food allergy research and clinical communities, ensuring safety, quality, and efficacy across various allergens. The development of these new standardised allergen products allows for easy expansion of the product portfolio with further allergens. The addition of egg and milk challenge meals to…
PR Newswire
12/06/2025

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange…

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in the execution of its oncology strategy Acquisition of CureVac will complement BioNTech’s capabilities and proprietary technologies in mRNA design, delivery formulations, and mRNA manufacturing Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5...
Nasdaq GlobeNewswire
12/06/2025

Major shareholder announcement

Pursuant to Section 30 of the Danish Capital Markets Act, Novonesis hereby announces that BlackRock, Inc. has notified Novonesis of the following status relating to the position of share capital attached to shares and share capital through financial instruments.Per June 10, 2025, BlackRock, Inc. has adjusted its holding of shares to an equivalent of 22,753,631 shares, corresponding to 4.85% of the total share capital attached to shares. The combined total of share capital attached to shares...
Nasdaq GlobeNewswire
12/06/2025

MolecuLight® Imaging Significantly Improves Outcomes and Cuts Costs for Deep…

Key findings that underscore the power of MolecuLight imaging: Key findings that underscore the power of MolecuLight imaging: "This study demonstrates that MolecuLight delivers tangible benefits in clinical wound management and also serves as a valuable teaching tool in our daily practice. The ability to visualize bacterial presence in real time allows us to more effectively guide younger physicians in understanding critical principles of infection control and intraoperative wound…
PR Newswire
12/06/2025

Amid crisis and cost cutting fatigue, Europeans splash out on comfort and…

Circana's latest report, Eat Play Love, reveals that consumers across Europe are prioritising purchases that give them more control over their lives and offer "mini moments of bliss." The data, drawn from Circana's extensive coverage of European food retail, foodservice, prestige beauty, and toys, shows a striking shift toward self-soothing consumption. Circana's latest report, Eat Play Love, reveals that consumers acrossEuropeare prioritising purchases that give them more control...
PR Newswire
12/06/2025

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

"The breadth of data that we share at this year's EHA congress demonstrates Sobi's comprehensive approach to addressing rare conditions in haematology. We are proud to contribute to advancing the science in several indications from early clinical phases in diffuse large B-cell lymphoma to clinical and real-world evidence in myelofibrosis, primary hemophagocytic lymphohistiocytosis, immune thrombocytopenia and paroxysmal nocturnal haemoglobinuria," said Lydia Abad-Franch, MD, Head of…
PR Newswire
12/06/2025

Medical Second Opinion Market to Hit USD 19.03 Billion by 2029, Driven by Cancer…

Claim Your Free Report: https://reports.valuates.com/request/sample/QYRE-Auto-7W16107/Global_and_India_Medical_Second_Opinion_Market Claim Your Free Report:https://reports.valuates.com/request/sample/QYRE-Auto-7W16107/Global_and_India_Medical_Second_Opinion_Market Major Factors Driving the Growth of Medical Second Opinion Market: The Medical Second Opinion Market is gaining substantial momentum as patients increasingly prioritize diagnostic certainty and value-based healthcare...
PR Newswire
12/06/2025

Moon Surgical Discusses Maestro at NVIDIA GTC Paris, Celebrating 1,300+…

Physical AI is the integration of perceptive hardware with powerful local computing, enabling software-defined systems to understand and interact with the physical world in real time. From system deployment to procedural subtasks, physical AI combines the forces of robotic devices and agentic AI, it is the infrastructure layer to the operating room. Maestro uses ambient sensing, and robotics powered by NVIDIA Holoscan and NVIDIA IGX technologies to bring this type of capability to the clinical…
PR Newswire
12/06/2025

Implantica announces new real-world Swiss study on 99 RefluxStop™ patients…

Patients with large hernia, where the stomach protrudes through the opening of the diaphragm, have so far been difficult to treat with existing methods. The key finding from this paper shows RefluxStop™ is safe and effective in both large and small hernia size patient groups, with no significant difference in adverse events. Furthermore, all patients reported a significant improvement in their GERD-HRQL scores after the RefluxStop™ procedure, including those with large hiatal hernia (4-10 cm)…
PR Newswire
12/06/2025

Oxurion boekt vooruitgang met de voorgenomen overname van Axiodis

Leuven, BELGIË – 12 juni 2025 – 8u30 CET – Oxurion NV (Euronext Brussel: OXUR), een biofarmaceutisch bedrijf met hoofdkantoor in Leuven, kondigt aan dat de opschortende voorwaarde met betrekking tot het voorafgaand informatie- en raadplegingsrecht van de werknemers, overeenkomstig artikel L.23-10-1 van het Franse Wetboek van Koophandel, is vervult…
Actusnews Wire
12/06/2025

Oxurion moves forward with the planned acquisition of Axiodis

Leuven, BELGIUM – June 12, 2025 at 8:30 AM CET, Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company based in Leuven, announces the lifting of the condition precedent relating to the completion of the employee information process as per Article L.23-10-1 of the French Commercial Code. This milestone represents a key step towards the…
Actusnews Wire
12/06/2025

Enterome raises $19 million to fund clinical development of its OncoMimics™…

Proceeds to fund Phase 1/2 trial of EO2463 OncoMimics™, as a monotherapy or in combination, to treat multiple forms of indolent non-Hodgkin lymphoma (iNHL)$9 million from new investor The Institute for Follicular Lymphoma Innovation (IFLI) $10 million from existing specialist investors, including The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) Paris, France – June 12, 2025Enterome SA, a clinical-stage company developing first-in-class OncoMimics™...
Nasdaq GlobeNewswire
12/06/2025

Bavarian Nordic Initiates Phase 3 Study of Chikungunya Vaccine in Children

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine.COPENHAGEN, Denmark, June 12, 2025– Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a Phase 3 clinical study of its single-dose, virus-like particle (VLP) chikungunya vaccine, CHIKV VLP in children 2 to 11 years of age.This first trial of CHIKV VLP in a pediatric population aims to expand the target population for the vaccine, currently approved for...
Nasdaq GlobeNewswire
12/06/2025

Real-world prospective data confirms improved risk stratification in multiple…

The study demonstrates that integrating SKY92 into routine practice can enhance prognostic accuracy and support personalized treatment planning, marking an important milestone toward the widespread clinical implementation of the SKY92 classifier in MM management. The PROMMIS study was made possible through the close collaboration of nine renowned U.S. hospitals and research centers. Together, these institutions enrolled 251 newly diagnosed multiple myeloma (NDMM) patients between 2018 and 2021…
PR Newswire
12/06/2025

Novartis Fabhalta® shows statistically significant and clinically meaningful…

In the Phase IIIB APPULSE-PNH study, adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched to Fabhalta experienced clinically meaningful improvements in hemoglobin (Hb) levels of 2.01 g/dL on average 1,2 APPULSE-PNH evaluated Fabhalta in a population with higher baseline hemoglobin (Hb) levels than those enrolled in the pivotal Phase III program, expanding the clinical evidence base 1 ,2 No patients treated with Fabhalta required transfusions,...
Nasdaq GlobeNewswire
12/06/2025

Outcomes4Me Acquires Germany's Mika Health App to Accelerate AI-Driven Patient…

Outcomes4Me, which supports more than 280,000 cancer patients, recently finalized a $21M funding round, emphasizing the company's plans to expand both its patient community and commercial business globally. This acquisition strengthens Outcomes4Me's platform with Mika's proven interventions for real-time symptom management, behavioral coaching, and emotional support, setting a new global standard for digital oncology support. It also allows Outcomes4Me to scale faster in European markets…
PR Newswire
12/06/2025

AB Science announces issuance of a Canadian patent protecting the composition of…

PRESS RELEASEAB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036THIS PATENT COMPLETES INTELLECTUAL PROPERTY COVERAGE FOR AB8939 ACROSS ALL KEY GEOGRAPHIC AREAS WHERE IT COULD BE MARKETED, INCLUDING EUROPE, USA, CHINA, JAPAN AND SOUTH KOREA, INDIA, ISRAEL, LATIN AMERICA, AND AUSTRALIAParis, 12 June, 2025, 8am CETAB Science SA(Euronext -...
Nasdaq GlobeNewswire
12/06/2025

Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European…

Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activityDZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus erythematosus (SLE)At Week 48, more individuals receiving DZP experienced no or low disease activity compared to standard of care with differences observed as early as Week 12BRUSSELS and CAMBRIDGE, Mass., June12, 2025(GLOBE...
Nasdaq GlobeNewswire
12/06/2025

Multiple Sclerosis Market to Grow Rapidly at a CAGR of 3.8% During the Forecast…

The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated 1.6 million diagnosed cases of multiple sclerosis across the 7MM. This number is expected to increase at a CAGR of 1.4% over the forecast period from 2025 to 2034. The severity and progression of multiple sclerosis can vary greatly among individuals. As of 2024, there were an estimated1.6 milliondiagnosed cases of multiple sclerosis across the 7MM. This number is...
PR Newswire
11/06/2025

DBV Technologies Announces the Voting Results of its 2025 Combined General…

DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting Shareholders approved all proposed resolutions DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company (the “ Company ”), held its Combined General Meeting (the “ General Meeting ”). The General Meeting was chaired by Michel de Rosen, Chairman of the Company. The Company’s shareholders approved all resolutions submitted by the Board...
Nasdaq GlobeNewswire
11/06/2025

Alvotech’s Private Placement Completed with Delivery of SDRs and Shares to…

Alvotech (NASDAQ: ALVO, ALVO-SDB, the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the completion of a private placement that was carried out on June 4, 2025, directed to Swedish and international institutional investors. About 40 institutional investors participated in the placement. About 60% of the demand came from institutional investors based in Sweden, Norway or the UK, and about 30%...
Nasdaq GlobeNewswire
11/06/2025
Altri  Comunicati